Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 198.27M P/E - EPS this Y 50.00% Ern Qtrly Grth -
Income -113.87M Forward P/E -1.63 EPS next Y -37.00% 50D Avg Chg -11.00%
Sales 60.28M PEG -5.63 EPS past 5Y - 200D Avg Chg -38.00%
Dividend N/A Price/Book 1.74 EPS next 5Y 1.00% 52W High Chg -67.00%
Recommedations 2.40 Quick Ratio 2.66 Shares Outstanding 246.82M 52W Low Chg 1.00%
Insider Own 0.21% ROA -28.22% Shares Float 665.36M Beta 2.39
Inst Own 70.02% ROE -187.61% Shares Shorted/Prior 3.11M/2.93M Price 0.88
Gross Margin -109.87% Profit Margin -188.90% Avg. Volume 892,806 Target Price 3.50
Oper. Margin -21,582.68% Earnings Date Mar 6 Volume 380,104 Change -3.06%
About Adaptimmune Therapeutics plc

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers. The company has strategic collaboration and license agreement with Genentech, Inc. and F. Hoffman-La Roche Ltd to develop personalized allogeneic and allogeneic T-cell therapies; research, collaboration, and license agreement with Universal Cells, Inc.; third-party collaborations with Noile-Immune and Alpine Immune Sciences; and strategic alliance agreement with the MD Anderson Cancer Center. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.

Adaptimmune Therapeutics plc News
03/27/24 Results of Adaptimmune's SPEARHEAD-1 Trial with Afami-cel in Advanced Sarcomas Published in the Lancet
03/08/24 Adaptimmune Therapeutics Full Year 2023 Earnings: EPS Beats Expectations, Revenues Lag
03/07/24 Adaptimmune Therapeutics PLC Reports Q4 and Full Year 2023 Financial Results
03/07/24 Adaptimmune Therapeutics plc (NASDAQ:ADAP) Q4 2023 Earnings Call Transcript
03/06/24 Adaptimmune Reports Q4/Full Year 2023 Financial Results and Business Updates
02/27/24 Adaptimmune Hires Chief Commercial Officer in Advance of Q3 2024 PDUFA Date for Afami-cel, a Late-stage Product in the Company's Sarcoma Franchise
02/21/24 Adaptimmune to Report Q4 and Full Year 2023 Financial and Business Updates on Wednesday, March 6, 2024
02/16/24 15 Top Performing European Stocks So Far in 2024
02/13/24 Adaptimmune Therapeutics PLC (ADAP) Stock Moves -1.24%: What You Should Know
01/31/24 Adaptimmune Announces U.S. FDA Acceptance of Biologics License Application for Afami-cel for the Treatment of Advanced Synovial Sarcoma with Priority Review
01/30/24 Baillie Gifford Increases Stake in Adaptimmune Therapeutics PLC
01/17/24 Adaptimmune Therapeutics (NASDAQ:ADAP shareholders incur further losses as stock declines 22% this week, taking three-year losses to 88%
01/16/24 Adaptimmune (ADAP) Surges More Than 80% in a Month: Here's Why
01/04/24 Adaptimmune Projects Sarcoma Franchise to Deliver US Peak Year Sales up to $400 Million - Presentation at JP Morgan Healthcare Conference
12/07/23 Positive week for Adaptimmune Therapeutics plc (NASDAQ:ADAP) institutional investors who lost 68% over the past year
12/06/23 Adaptimmune Completes Submission of Rolling Biologics License Application (BLA) to U.S. FDA for Afami-cel for the Treatment of Advanced Synovial Sarcoma
11/30/23 Adaptimmune (ADAP) Rises as GSK Transfers T-Cell Therapy IND
08:00 AM Adaptimmune Receives Transfer of IND for Lete-cel Program
11/13/23 Adaptimmune Therapeutics PLC (ADAP) Loses -28.34% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
11/13/23 Adaptimmune Therapeutics plc (NASDAQ:ADAP) Q3 2023 Earnings Call Transcript
ADAP Chatroom

User Image LonoTrader Posted - 21 hours ago

@Davington @StrandMan $LXRX and $ADAP are my two current holdings. Hopefully I can amass a small fortune to reinvest in $VSTM before institutions decide they’ve bled enough shares from retail traders and decide they want to make money off those same retail traders by getting them to chase (scarce shares) on the rise 😉.

User Image immuz Posted - 23 hours ago

$ADAP if we dip below $1.50 I will buy a couple thousand more shares.

User Image CliffordCapital Posted - 1 day ago

$ADAP & $MIST going according to plan! Come on $HUMA

User Image Clipping_Coupons Posted - 1 day ago

$ADAP Iovance did not start ascending until 4 months before padooooooofa. April will be critical for Ineptimmune. 4 CRs in ovarian will be better.

User Image Clipping_Coupons Posted - 1 day ago

$ADAP $0.25 day is coming anon.

User Image S_Franconi Posted - 1 day ago

@immuz $AUPH $SCPH $ADAP $AADI $BLUE AUPH put itself up for a fire sale, I know nothing about SCPH, BLUE is a executive enrichment disaster, material accounting understatements, which may not own the science on it's top two products. ADAP - we've discussed. AADI had an extreme over reaction to news.

User Image FringDook Posted - 1 day ago

$ADAP

User Image WarrenPsnik Posted - 1 day ago

$ADAP Looking for a sustained move up from this point. Especially with Ecor purchase ...

User Image BTCSATS Posted - 1 day ago

$ADAP Solid week at price support, as pointed out in my previous post thus far.

User Image BiotechJohn Posted - 1 day ago

$ADAP link to paper https://www.sciencedirect.com/science/article/abs/pii/S0140673624003192?dgcid=author

User Image YouVSYou Posted - 1 day ago

$AKBA Lovers should check out $ADAP for a nice ride into August 💫 As well Congrats Bulls

User Image GinoGino Posted - 1 day ago

$ADAP Extremely likely. The company had ongoing dialogue with FDA during the long rolling BLA process to ensure all their concerns were addressed. FDA normally refers such filings to an advisory committee prior to making a decision. The fact they hadn't done so here, at least thus far, indicates they are satisfied and are inclined to approve the BLA.

User Image leonardi Posted - 1 day ago

$ADAP https://www.newsfilecorp.com/release/203159 so as per what was shared by MGMT with these results we should get full approval? Or I understood it wrong

User Image newsfile_corp Posted - 1 day ago

https://nfne.ws/203159 $ADAP @Adaptimmune #ADAP #celltherapy #oncology #sarcoma #Chemicals #Biotechnology #HealthCare #NASDAQ #Investing

User Image Stock_Titan Posted - 1 day ago

$ADAP Results of Adaptimmune's SPEARHEAD-1 Trial with Afami-cel in Advanced Sarcomas Published in the Lancet https://www.stocktitan.net/news/ADAP/results-of-adaptimmune-s-spearhead-1-trial-with-afami-cel-in-epxajbap744a.html

User Image Jacobi Posted - 1 day ago

$ADAP in at 1.55

User Image YouVSYou Posted - 1 day ago

$ADAP

User Image YouVSYou Posted - 1 day ago

$ADAP Doubles Next big PDUFA coming

User Image GinoGino Posted - 1 day ago

$ADAP Add, and this is the last time for me, no more shares to buy here! Now let's how my patience here pays off and how my thesis materializes.

User Image Longroader Posted - 2 days ago

$ADAP EcoR1 adding means a lot. The platform is valuable. $375m mcap is still v cheap here.

User Image Clipping_Coupons Posted - 2 days ago

$ADAP ON: of EcoR1 “We often invest in companies that are unfollowed, unloved, misunderstood or left for dead that have great downside protection. These are extraordinary companies that have found themselves in an extraordinary time.”

User Image Clipping_Coupons Posted - 2 days ago

Question is why did ON of EcoR1 pick $ADAP? Very good, but dated article, but I’m sure the fundamental investing principles endure. Of note for the beleaguered long term holders: “Success is often idiosyncratic and not repeatable, so these are not companies that you can buy and hold forever.” He’ll flip it. Don’t count on $77. https://whalewisdomalpha.com/ecor1-now-owns-8-of-xencor-oleg-nodelman-the-warren-buffett-of-biotech/

User Image SkSk_ Posted - 2 days ago

$ADAP ECOR1 added 8M more shares a few weeks ago, filing confirmed today. Big conviction from them is a very good sign. I’m loading some $2 strike September calls which cover PDUFA, but mainly here for the run up.

User Image leonardi Posted - 2 days ago

$ADAP last time ecor increased position we went from 40 cents to 2.05. Now we at 1.50 can we $4 soon?

User Image Bionco Posted - 2 days ago

$ADAP nice recover

User Image JoshThe3rd Posted - 2 days ago

$ADAP ecor1 has 10% ownership here now, not bad

User Image dhovekamp42 Posted - 2 days ago

$ADAP can understand the short term catalysts here or wait until April https://journey.ct.events/view/91456037-e856-481d-847b-d1638353ce60

User Image lob11 Posted - 2 days ago

$ADAP So, it was ECOR who bought that 8mil. block last week. Ok, den.

User Image Streetbullx2 Posted - 2 days ago

$AKBA ok tomorrow is do or die. $ADAP day trading it for now, shorts will try to get it down to the 1.20s since the PDUFA is so far out. $MCRB dont like the vote to raise tge AS. $XBI

User Image Clipping_Coupons Posted - 2 days ago

$ADAP

Analyst Ratings
Barclays Underweight Aug 10, 23
EF Hutton Buy Aug 10, 23
EF Hutton Buy Jun 5, 23
EF Hutton Buy Jun 2, 23
EF Hutton Buy May 26, 23
EF Hutton Buy Apr 17, 23
EF Hutton Buy Apr 11, 23
EF Hutton Buy Mar 6, 23
EF Hutton Buy Jan 5, 23
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Rawcliffe Adrian Chief Executive Offi.. Chief Executive Officer Jan 16 Sell 0.73 39,384 28,750 44,848 01/17/24
Norry Elliot Chief Medical Office.. Chief Medical Officer Jan 16 Sell 0.71 20,563 14,600 19,257 01/17/24
Lunger John Chief Patient Supply.. Chief Patient Supply Officer Jan 16 Sell 0.71 22,795 16,184 19,015 01/17/24
Bertrand William C JR Chief Operating Offi.. Chief Operating Officer Jan 16 Sell 0.71 23,589 16,748 20,201 01/17/24
Norry Elliot Chief Medical Office.. Chief Medical Officer Jan 11 Sell 0.85 11,808 10,037 11,841 01/12/24
Bertrand William C JR Chief Operating Offi.. Chief Operating Officer Jan 11 Sell 0.85 9,229 7,845 7,874 01/12/24
Rawcliffe Adrian Chief Executive Offi.. Chief Executive Officer Jan 11 Sell 0.85 29,202 24,822 26,388 01/12/24
Lunger John Chief Patient Supply.. Chief Patient Supply Officer Jan 11 Sell 0.85 9,229 7,845 7,874 01/12/24
Rawcliffe Adrian Chief Executive Offi.. Chief Executive Officer Sep 01 Sell 0.78 2,403 1,874 3,449 09/01/23
Menzel Garry E Director Director Jul 10 Sell 0.9108 47,702 43,447 75,056 07/10/23
Rawcliffe Adrian Chief Executive Offi.. Chief Executive Officer Jun 27 Sell 0.92 2,333 2,146 3,519 06/27/23
Piccina Cintia Chief Commercial Off.. Chief Commercial Officer Jan 31 Sell 1.8696 11,890 22,230 19,535 01/31/23
Lunger John Chief Patient Supply.. Chief Patient Supply Officer Jan 17 Sell 1.858 4,440 8,250 7,264 01/17/23
Bertrand William C JR Chief Operating Offi.. Chief Operating Officer Jan 17 Sell 1.858 4,440 8,250 7,264 01/17/23
Norry Elliot Chief Medical Office.. Chief Medical Officer Jan 17 Sell 1.858 2,159 4,011 3,491 01/17/23
Rawcliffe Adrian Chief Executive Offi.. Chief Executive Officer Jan 17 Sell 1.858 10,057 18,686 13,351 01/17/23
Bertrand William C JR Chief Operating Offi.. Chief Operating Officer Jan 11 Sell 1.73 8,816 15,252 8,121 01/12/23
Lunger John Chief Patient Supply.. Chief Patient Supply Officer Jan 11 Sell 1.73 8,816 15,252 8,121 01/12/23
Norry Elliot Chief Medical Office.. Chief Medical Officer Jan 11 Sell 1.73 11,292 19,535 12,191 01/12/23
Rawcliffe Adrian Chief Executive Offi.. Chief Executive Officer Jan 11 Sell 1.73 31,805 55,023 24,882 01/12/23
Bertrand William C JR Chief Operating Offi.. Chief Operating Officer Jan 04 Sell 1.694 3,584 6,071 5,781 01/04/23
Lunger John Chief Patient Supply.. Chief Patient Supply Officer Jan 04 Sell 1.6940 1,100 1,863 1,725 01/04/23
Norry Elliot Chief Medical Office.. Chief Medical Officer Jan 04 Sell 1.6940 876 1,484 1,361 01/04/23
Rawcliffe Adrian Chief Executive Offi.. Chief Executive Officer Jan 04 Sell 1.6940 5,073 8,594 6,631 01/04/23
Rawcliffe Adrian Chief Executive Offi.. Chief Executive Officer Sep 01 Sell 1.9689 2,536 4,993 3,316 09/01/22
Lunger John Chief Patient Supply.. Chief Patient Supply Officer Aug 01 Sell 1.7735 2,983 5,290 4,829 08/01/22
Piccina Cintia Chief Commercial Off.. Chief Commercial Officer Aug 01 Sell 1.7735 21,040 37,314 34,824 08/01/22
Lunger John Chief Patient Supply.. Chief Patient Supply Officer Jul 05 Sell 1.6781 1,973 3,311 3,104 07/05/22
Rawcliffe Adrian Chief Executive Offi.. Chief Executive Officer Jun 27 Sell 1.63 2,562 4,176 3,290 06/27/22
Wood Gavin Chief Financial Offi.. Chief Financial Officer May 20 Buy 0.2904 39,000 11,326 96,000 05/23/22
Bertrand William C JR Chief Operating Offi.. Chief Operating Officer Jan 18 Sell 3.1918 4,368 13,942 7,336 01/18/22
Lunger John Chief Patient Supply.. Chief Patient Supply Officer Jan 18 Sell 3.1918 4,368 13,942 7,336 01/18/22
Norry Elliot Chief Medical Office.. Chief Medical Officer Jan 18 Sell 3.1918 2,121 6,770 3,529 01/18/22
Rawcliffe Adrian Chief Executive Offi.. Chief Executive Officer Jan 18 Sell 3.1918 11,096 35,416 12,312 01/18/22
Bertrand William C JR Chief Operating Offi.. Chief Operating Officer Jan 11 Sell 3.55 6,018 21,364 3,754 01/13/22
Lunger John Chief Patient Supply.. Chief Patient Supply Officer Jan 11 Sell 3.55 4,846 17,203 1,749 01/13/22
Norry Elliot Chief Medical Office.. Chief Medical Officer Jan 11 Sell 3.55 4,624 16,415 1,383 01/13/22
Rawcliffe Adrian Chief Executive Offi.. Chief Executive Officer Jan 11 Sell 3.55 17,408 61,798 3,356 01/13/22